Astellas inks partnership on rice-based oral vaccine

7 December 2017

Japanese drug major Astellas Pharma (TYO: 4503) is partnering with academia to develop rice-based vaccines, which will have simpler storage requirements than traditional vaccines.

Astellas has signed a collaboration agreement with the Institute of Medical Science, the University of Tokyo, Chiba University and environmental control equipment maker Asahi Kogyosha aiming at the practical application of the rice-based oral vaccine “MucoRice-CTB.”

This research program has been designated as a project under Cyclic Innovation for Clinical Empowerment (CiCLE) and will be supported by the Japan Agency for Medical Research and Development (AMED).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK